<DOC>
	<DOC>NCT01418846</DOC>
	<brief_summary>The purpose of this study is to investigate the intra-saliva penetration of voriconazole in different subpopulations. The goal is to develop, optimize and validate an easy, non-invasive and painless procedure for Therapeutic Drud Monitoring of voriconazole that can be used in children, ambulatory patients and in patients in whom blood drawing is difficult.</brief_summary>
	<brief_title>Determination of Voriconazole Levels in Saliva - Validation in Specific Subsets of Patients</brief_title>
	<detailed_description />
	<mesh_term>Voriconazole</mesh_term>
	<criteria>patients from the adult hematology ward treated with voriconazole pediatric patients treated with voriconazole, age 518 years patients from the pneumology ward treated with voriconazole Age under 5 years Women who are pregnant or lactating Mucositis stage 3 or 4 (WHO) Patients which received the following drugs within 14 days before study entry: rifampicin, rifabutin, carbamazepine, phenytoin, phenobarbital, nevirapine, efavirenz and barbiturates. Patients which received the following drugs within 24hours before study entry: quinidine, ergotamine, sirolimus, saquinavir, amprenavir, nelfinavir, ritonavir and sulphonylureas.</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>voriconazole</keyword>
	<keyword>saliva</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>